Additional Metadata
Persistent URL dx.doi.org/10.1158/1078-0432.Ccr-18-1943, hdl.handle.net/1765/116149
Journal Clinical Cancer Research
Rights no subscription
Citation
Laere, B, Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.J., Van Oyen, P., … Dirix, L.Y. (2019). TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 25(6), 1766–1773. doi:10.1158/1078-0432.Ccr-18-1943